The new drug developed by the Tomsk сompany IPHAR has a mechanism of action that differs from that of its predecessors and thus, opens new prospects in the treatment of parkinsonism.
“The nature of the disease is not completely understood, but it is related to the death of neurons that are responsible for the so-called dopamine innervation of the brain,” explains Professor Veniamin Khazanov, General Director of IPHAR. – According to medical specialists, the progress in the treatment of the disease is only possible with the search for drugs with a new mechanism of action, since the drugs with a known mechanism of action already have exhausted their potential for pharmacotherapy. The drug that we are developing now has the mechanism of action that differs from all known mechanisms. All the time we find out something new in its effects on the nervous tissue. It does not fit into the usual framework and somehow improves the work of neurons in some surprising way. That is why we are so eagerly waiting for the beginning of clinical trials, which will show whether we get a new medicine.”
The head of IPHAR said that now the main preclinical studies are almost completed and by the end of the year, the company plans to request a clinical trial authorisation from the Ministry of Health.
Tomsk already receives letters and calls from Russia and abroad from those who wish to participate in the clinical trials and potential buyers. The development of Tomsk innovators aroused great interest of the local and foreign pharmaceutical companies.
Innovative Pharmacology Research, LLC (IPHAR) was founded in 2004 as a drug development organization. In 2012 the company became the participant of «Skolkovo» project and was included into the Innovative Territorial Cluster «Pharmaceutics, medical technology and IT». In 2013 IPHAR became an accredited drug development collective use center of «Skolkovo Technopark».